Fay Touti

Company: Apellis Pharmaceuticals

Job title: Director, Oligonucleotide & Conjugation Chemistry

Seminars:

Targeting Complement C3 via Intrathecal siRNA: A Novel Approach to Neuroinflammation in Neurodegeneration 4:00 pm

Early discovery and translational journey of Apellis’ siRNA program targeting complement C3 for neurodegenerative diseases Insights from siRNA screening and optimization to enable potent, durable knockdown of C3 in non-human primates (NHPs), setting the stage for clinical translation Exploring the potential of intrathecal complement inhibition as a first-line therapy and its synergistic use in combination…Read more

day: Day 1